- Home
- LGVN vs IBIO Comparison
LGVN vs IBIO Comparison
Compare LGVN & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- IBIO
- Stock Information
- Founded
- LGVN 2014
- IBIO 2008
- Country
- LGVN United States
- IBIO United States
- Employees
- LGVN N/A
- IBIO N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- IBIO Health Care
- Exchange
- LGVN Nasdaq
- IBIO Nasdaq
- Market Cap
- LGVN 16.4M
- IBIO 16.4M
- IPO Year
- LGVN 2021
- IBIO N/A
- Fundamental
- Price
- LGVN $0.89
- IBIO $0.87
- Analyst Decision
- LGVN Strong Buy
- IBIO Strong Buy
- Analyst Count
- LGVN 2
- IBIO 2
- Target Price
- LGVN $6.50
- IBIO $5.50
- AVG Volume (30 Days)
- LGVN 399.0K
- IBIO 376.3K
- Earning Date
- LGVN 11-11-2025
- IBIO 11-11-2025
- Dividend Yield
- LGVN N/A
- IBIO N/A
- EPS Growth
- LGVN N/A
- IBIO N/A
- EPS
- LGVN N/A
- IBIO N/A
- Revenue
- LGVN $2,073,000.00
- IBIO $400,000.00
- Revenue This Year
- LGVN N/A
- IBIO N/A
- Revenue Next Year
- LGVN N/A
- IBIO N/A
- P/E Ratio
- LGVN N/A
- IBIO N/A
- Revenue Growth
- LGVN 68.67
- IBIO 77.78
- 52 Week Low
- LGVN $0.63
- IBIO $0.56
- 52 Week High
- LGVN $2.48
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- LGVN 48.25
- IBIO 60.39
- Support Level
- LGVN $0.73
- IBIO $0.78
- Resistance Level
- LGVN $0.82
- IBIO $0.86
- Average True Range (ATR)
- LGVN 0.03
- IBIO 0.04
- MACD
- LGVN 0.02
- IBIO 0.00
- Stochastic Oscillator
- LGVN 94.35
- IBIO 95.55
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.